12040 115th Ave., NE
Kirkland, WA 98034
Office: (425) 823-0400
Fax: (425) 823-8508
SMALL MOLECULE APPROACH TO TREATING PARKINSON'S DISEASE
ProteoTech is one of a few companies at the forefront of developing disease-modifying small molecule compounds targeted at inhibiting the formation and aggregation of a protein called alpha-synuclein found in the brains of patients with Parkinson's and believed to play an important role in this disease. Alpha-synuclein aggregates inside dopamine-producing neurons form large aggregates called Lewy bodies in brains of Parkinson's patients.
ProteoTech's lead small molecule, Synuclere™ targets alpha-synuclein aggregation and is currently in late pre-clinical stages of development. This research has been accomplished in partnership with funding from The Michael J. Fox Foundation for Parkinson's Research LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) award program.
The major goal of our Parkinson's disease research is to identify small molecule compounds that prevent the intracellular formation and aggregation of alpha-synuclein which is believed to play an important role in the progression of Parkinson's disease. Synuclere™ and related lead compounds currently in development achieve this goal by preventing or reducing alpha-synuclein monomers and oligomers in brain.
Note: Images showing the progression of Parkinson's disease
Source: Institute for Neurodegenerative Disorders firstname.lastname@example.org